Abbott has signed a licensing agreement with ALZpath, a provider of blood-based diagnostics for Alzheimer's disease, for its proprietary phosphorylated Tau 217 antibody. The agreement aims to enhance the accessibility of high-performance testing for clinicians and patients globally. The pTau217 antibody is among the most clinically validated for detecting Alzheimer's disease pathology, backed by more than 200 peer-reviewed publications across 18 countries. It demonstrates high accuracy and sensitivity in identifying Alzheimer's disease biology.

The partnership addresses the growing need for scalable diagnostics as disease-modifying therapies expand. ALZpath's pTau217 antibody provides a less invasive and more cost-effective alternative to PET imaging and cerebrospinal fluid (CSF) analysis, which are often difficult to deploy at scale. Blood-based biomarkers are also expected to play a role in monitoring disease progression and treatment response in routine clinical practice.

Strategic Implications

Mike Banville, CEO of ALZpath, stated that the agreement reinforces the company's leadership in blood-based Alzheimer's testing. He noted that partnering with a global healthcare leader like Abbott enables high-performance testing to reach a wider audience. The collaboration focuses on integrating the antibody into routine care, including primary care settings, to assist patients in need.

Abbott's Commitment to Brain Health

John Frels, vice president of research and development in Abbott's Core Diagnostics business, highlighted the company's decade-long focus on advancing brain health science. Abbott previously pioneered the first FDA cleared rapid blood test for assessing mild traumatic brain injuries using objective biomarker data. Frels emphasized that such collaborations accelerate research, clinical trials, and patient care in Alzheimer's disease.

Abbott India Limited has secured shareholder approval to appoint Mr. James Wenner and Mr. Neeraj Jain to its Board. The resolutions were passed through a remote e-voting process, which concluded on June 16, 2026. Mr. James Wenner has been appointed as a Director effective April 23, 2026, while Mr. Neeraj Jain joins as an Independent Director for a period of three consecutive years effective April 25, 2026.

The postal ballot results were scrutinized by Ms. Fatema Fatehi, a Practicing Company Secretary from M/s. Khumri Wagh Fatehi & Associates LLP. The voting process was facilitated by KFin Technologies Limited. The record date for determining shareholder eligibility was May 8, 2026, and the remote e-voting period was open from May 18, 2026, to June 16, 2026.

Voting Results Summary

The resolutions received overwhelming support from shareholders across all categories. The total number of votes polled for the resolutions was 17,645,157, representing 83.04% of the total outstanding shares.

Detailed Breakdown

The Promoter and Promoter Group cast 15,934,048 votes in favour of both resolutions, constituting 100% of their holdings. Public Institutions and Non-Institutions also supported the appointments significantly. Public Institutions cast 1,672,213 votes in favour for Mr. Wenner's appointment and 1,672,687 votes for Mr. Jain's appointment.

The Scrutinizer's Report confirmed that the requisite majority was obtained as per the provisions of the Companies Act, 2013, and the SEBI Listing Regulations, 2015. The results have been submitted to the stock exchanges and are available on the company's website.